

FEATURE

# Man's Best Friend

in More Ways Than One

*Cancer drug development typically begins with in vitro research before proceeding through varying degrees of investigation in cell lines and laboratory animals, eventually culminating in human clinical trials. However, this often arduous development path may now find an ally in a relatively new branch of oncology research, referred to as comparative oncology. Initiated and directed by Chand Khanna, D.V.M., Ph.D., the CCR Comparative Oncology Program complements translational research through the characterization of relevant and naturally occurring cancer models that develop in pet animals as a window to evaluate novel therapies.*

- [Comparative Oncology Trials Consortium](#)
- [Agreements](#)
- [Clinical Trials](#)
- [Development Path](#)
- [Trial Development Overview](#)
- [Pharmacodynamic Core](#)
- [News & Publications](#)
- [Contact Information](#)



- [Cross-Reactivity Antibody Survey](#)
- [Canine Normal Tissue Database](#)
- [Tissue Microarrays](#)
- [Canine Comparative Oncology Genomics Consortium](#)
- [Pharmacodynamic Core](#)



- [Background](#)
- [What is Comparative Oncology?](#)
- [Comparative Oncology Trials Consortium \(COTC\)](#)
- [Clinical Trials](#)
- [Disease Information](#)
- [News & Publications](#)



- [Comparative Oncology Trials Consortium](#)
- [Canine Comparative Oncology Genomics Consortium](#)



[ANY QUESTIONS??](#)